• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    More Americans Know Their Streaming Platform Passwords by Heart Than Their Cholesterol Score, New Survey Reveals

    5/20/25 8:52:00 AM ET
    $DGX
    Medical Specialities
    Health Care
    Get the next $DGX alert in real time by email

    Quest's second "Know Your Health" survey explores Americans' perceptions and priorities on their well-being in 2025

    Nearly one-third of Americans say their doctors/HCPs do not take the time to discuss preventive care and wellness with them; More than half of millennials, Gen Z cite barriers to accessing medical care

    SECAUCUS, N.J., May 20, 2025 /PRNewswire/ -- questhealth.com, the consumer-initiated testing platform from Quest Diagnostics (NYSE:DGX), one of the nation's leading providers of diagnostic information services, today revealed the results of its second "Know Your Health" survey, conducted online by The Harris Poll among nearly 2,100 U.S. adults. Findings revealed that most Americans are eager to take an active role in their healthcare journey, with 92% actively preparing for their future health and healthcare needs, but many experience barriers to receiving care, feel their doctors do not focus enough on preventive care and wellness discussions, and have gaps in knowledge on important personal health information.

    "For too long, Americans have been passive recipients of their healthcare and health information," says Richard Adams, Senior Vice President and General Manager, Consumer at Quest Diagnostics. "As the survey shows, many Americans are motivated to take charge of their health, but they may be experiencing barriers to accessing care through traditional channels and are unsure of where to go for support. At Quest, we're turning that traditional model on its head by giving people access to physician-guided diagnostic lab testing so they can proactively manage their health and feel empowered on their wellness journey."

    Prioritizing Personal Health in a World Dominated by Digital 

    In today's world of constant connectivity, it's surprising how often our own health stats fall by the wayside. In fact, the survey revealed that 2 in 5 Americans (40%) know their streaming platform passwords by heart, while only 19% know their cholesterol score. Cholesterol levels can be tested with a blood test, helping identify whether someone may be at risk of developing heart disease—insights that might not otherwise be known, as someone with high cholesterol does not always exhibit symptoms.

    Family medical history, which can help identify increased risk of certain hereditary conditions, seemed to be lower on the priority list for younger generations, with more than half of Gen Z ages 18-28 (56%) knowing their streaming platform passwords by heart compared to their family medical history (31%).

    "Family medical history and insights from laboratory testing help serve as a blueprint for one's health — it gives individuals and medical professionals clues to assess the likelihood of developing certain conditions, including heart disease, diabetes, and even some cancers, in the future," said Mark Kruzel, MD, Medical Director for questhealth.com. "As a physician, it concerns me that many individuals surveyed want to be healthy, but aren't aware of basic health risks, which can often be lowered with preemptive behaviors."

    Social media has also continued to be a driving force for Americans' health habits, with 1 in 4 Americans (24%) admitting they get advice about health topics from social media influencers. Furthermore, one-third (33%) of Americans have acknowledged seeking medical care or testing after seeing someone's personal health stories shared on social media, and that jumps to more than half for Gen Z (52%) and Millennials ages 29-44 (51%).

    The Power of Healthy Habits 

    After navigating the unique challenges that the COVID-19 pandemic presented, Americans seem to be back on track with their personal health. In fact, 7 in 10 Americans (70%) rate their current health as good (54%) or excellent (16%). In comparison, 3 in 10 Americans (30%) describe their current overall health as fair (26%) or poor (5%). Among Americans who describe their overall health as fair or poor, more than half believe stress (60%), poor sleep (55%), and lack of exercise (51%) are contributing to their current health, while 3 in 10 say loneliness/isolation (30%) is a contributing factor.

    When it comes to healthy habits that Americans view as a priority, sleep is king. In fact, 71% of Americans say that good sleep tops this list, followed by proper hydration (65%) and regular exercise (62%). More than half of Americans say they prioritize taking vitamins and supplements (59%), eating a well-balanced diet (54%), and going for an annual physical (53%). In regard to annual appointments and lab testing, nearly half of Americans say getting bloodwork done each year (47%) and keeping up with preventive screenings (45%) are a priority to them.

    Planning for a Healthier Future 

    "Planning for a healthy future is about making daily informed decisions that invest in your overall well-being. Diagnostic testing can help provide valuable insights to help guide us, together with our healthcare providers, on steps to manage our overall health. Our health is the foundation of everything we do, and the best time to start investing in it is today," said Dr. Kruzel.

    A compelling majority of Americans (92%) are actively preparing for their future health and healthcare needs. About 3 in 5 Americans are doing so by trying to stay physically active (60%) and attempting to maintain a healthy diet (57%). More specifically, Boomers ages 61-79 (67%) are more likely than Gen Z (45%) or Millennials (58%) to say they try to stay physically active to prepare for their future health/health care needs.

    Preventive care also plays a key role, with about half of Americans focusing on regular checkups and screenings (51%) and relying on advice from doctors and healthcare professionals (49%) to help them identify their potential health risks early on. More than a quarter (27%) also use health apps or wearables to track vital signs, activity levels, and/or sleep patterns to stay on top of their well-being and make lifestyle adjustments based on the data.

    Navigating the Healthcare Landscape

    While Americans say they are prioritizing healthy behaviors—and 31% are trying to stay informed about changes in healthcare policies that could impact them—they also cite challenges to accessing care.  More than 1 in 3 Americans (37%) say they experienced barriers to receiving medical care in the past 12 months, ranging from long waits for scheduling appointments (10%) and being unsure about insurance coverage (9%) to potential cost considerations of lab work (8%). Barriers increased significantly with each generation: 12% of Boomers, 30% of Gen X ages 45-60, 53% of Millennials, and 62% of Gen Z. Additionally, 30% of Americans agree their doctor/health care professional does not take the time to talk to them about prevention and wellness.

    The survey also explored Americans' understanding of alternative modes of accessing healthcare. As it stands, nearly 2 in 3 Americans (63%) do not know it is possible to purchase their own lab tests without a doctor's visit. As Americans continue to focus on their health, building awareness of this pathway can help broaden testing accessibility and help people gain a better understanding of insights that can impact their overall health.  

    Questhealth.com provides access to consumer-initiated lab testing ranging from comprehensive health panels and STD tests to hormone health panels and tests to help identify or monitor chronic disease. While individuals can purchase tests online without a prior doctor's visit, a third-party physician reviews all test requests and is available to review results and, for some conditions, provide a prescription for treatment.

    "Consumer-initiated lab testing through Quest makes the process simple for consumers by providing access to the same quality lab tests that doctors use and recommend by way of questhealth.com, with the benefit of physician-guided care," said Dr. Kruzel.

    For more information, please visit questhealth.com.

    Survey Methodology 

    This survey was conducted online within the United States by The Harris Poll on behalf of Quest Diagnostics from March 11-13, 2025, among 2,087 adults ages 18+. The sampling precision of Harris online polls is measured by using a Bayesian credible interval.  For this study, the sample data is accurate to within +/- 2.5 percentage points using a 95% confidence level. For complete survey methodology, including weighting variables and subgroup sample sizes, please contact [email protected].

    About questhealth.com

    Quest empowers individuals with affordable, high-quality, trusted healthcare. The consumer-initiated test platform, questhealth.com, gives consumers more control over their own healthcare journeys, providing access to the same quality lab tests that doctors use and recommend, offering valuable information and insights about their health. questhealth.com offers more than 100 Quest Diagnostics lab tests in categories ranging from heart health and sexual health to allergies, fitness, and so much more. Tests available on questhealth.com also include physician oversight from an independent, third-party physician network, including test ordering and availability of a licensed physician to discuss test results. Consumers must be 18+ to purchase, and orders are not permitted in AK, AZ, or HI. For more information, please visit questhealth.com.

    About Quest Diagnostics

    Quest Diagnostics works across the healthcare ecosystem to create a healthier world, one life at a time. We provide diagnostic insights from the results of our laboratory testing to empower people, physicians and organizations to take action to improve health outcomes. Derived from one of the world's largest databases of de-identifiable clinical lab results, Quest's diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve healthcare management. Quest Diagnostics annually serves one in three adult Americans and half the physicians and hospitals in the United States, and our more than 55,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives and create a healthier world. www.QuestDiagnostics.com.

    questhealth.com logo

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/more-americans-know-their-streaming-platform-passwords-by-heart-than-their-cholesterol-score-new-survey-reveals-302460310.html

    SOURCE Quest Diagnostics

    Get the next $DGX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DGX

    DatePrice TargetRatingAnalyst
    1/30/2026$210.00Equal Weight → Overweight
    Barclays
    8/25/2025$194.00Outperform → Neutral
    Robert W. Baird
    4/2/2025$195.00Buy
    Redburn Atlantic
    3/4/2025$185.00Buy → Neutral
    Citigroup
    1/6/2025$169.00 → $174.00Market Perform → Outperform
    Leerink Partners
    12/17/2024$145.00 → $172.00Equal-Weight → Overweight
    Morgan Stanley
    12/10/2024$175.00 → $185.00Buy
    Jefferies
    10/23/2024$157.00 → $182.00Neutral → Outperform
    Robert W. Baird
    More analyst ratings

    $DGX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SVP for Diagnostic Services Plewman Patrick covered exercise/tax liability with 537 shares, sold $196,227 worth of shares (958 units at $204.83) and was granted 1,952 shares, increasing direct ownership by 3% to 15,838 units (SEC Form 4)

    4 - QUEST DIAGNOSTICS INC (0001022079) (Issuer)

    2/20/26 5:13:11 PM ET
    $DGX
    Medical Specialities
    Health Care

    Executive Vice President & CFO Samad Sam was granted 4,034 shares and covered exercise/tax liability with 1,865 shares, increasing direct ownership by 8% to 27,910 units (SEC Form 4)

    4 - QUEST DIAGNOSTICS INC (0001022079) (Issuer)

    2/20/26 5:12:39 PM ET
    $DGX
    Medical Specialities
    Health Care

    SVP & General Counsel Prevoznik Michael E sold $227,566 worth of shares (1,111 units at $204.83), was granted 2,013 shares and covered exercise/tax liability with 648 shares, increasing direct ownership by 0.67% to 38,371 units (SEC Form 4)

    4 - QUEST DIAGNOSTICS INC (0001022079) (Issuer)

    2/20/26 5:12:09 PM ET
    $DGX
    Medical Specialities
    Health Care

    $DGX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Quest Diagnostics upgraded by Barclays with a new price target

    Barclays upgraded Quest Diagnostics from Equal Weight to Overweight and set a new price target of $210.00

    1/30/26 6:40:39 AM ET
    $DGX
    Medical Specialities
    Health Care

    Quest Diagnostics downgraded by Robert W. Baird with a new price target

    Robert W. Baird downgraded Quest Diagnostics from Outperform to Neutral and set a new price target of $194.00

    8/25/25 8:10:20 AM ET
    $DGX
    Medical Specialities
    Health Care

    Redburn Atlantic initiated coverage on Quest Diagnostics with a new price target

    Redburn Atlantic initiated coverage of Quest Diagnostics with a rating of Buy and set a new price target of $195.00

    4/2/25 8:51:11 AM ET
    $DGX
    Medical Specialities
    Health Care

    $DGX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $DGX
    SEC Filings

    View All

    Quest Diagnostics Reports Fourth Quarter and Full Year 2025 Financial Results; Provides Guidance for Full Year 2026; Increases Quarterly Dividend 7.5% to $0.86 Per Share

    Fourth quarter revenues of $2.81 billion, up 7.1% from 2024Fourth quarter reported diluted earnings per share ("EPS") of $2.18, up 11.8% from 2024; and adjusted diluted EPS of $2.42, up 8.5% from 2024Full year revenues of $11.04 billion, up 11.8% from 2024Full year reported diluted EPS of $8.75, up 13.8% from 2024; and adjusted diluted EPS of $9.85, up 10.3% from 2024   Full year cash from operations of $1.89 billionFull year 2026 revenues expected to be between $11.70 billion and $11.82 billion Full year 2026 reported diluted EPS expected to be between $9.45 and $9.65; and adjusted diluted EPS expected to be between $10.50 and $10.70SECAUCUS, N.J., Feb. 10, 2026 /PRNewswire/ -- Quest Diagno

    2/10/26 6:47:00 AM ET
    $DGX
    Medical Specialities
    Health Care

    Quest Diagnostics Increases Dividend 7.5% To $0.86 Per Quarter, Marking 15 Consecutive Years of Dividend Increases; Announces $1 Billion Increase in Share Repurchase Authorization

    SECAUCUS, N.J., Feb. 10, 2026 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE:DGX), a leading provider of diagnostic information services, today announced that the Company's Board of Directors has authorized a 7.5% increase in its quarterly cash dividend to $0.86 per share from $0.80 per share. The increase is effective with the dividend payable on April 20, 2026 to shareholders of record of Quest Diagnostics common stock on April 6, 2026. With the increase, the annual cash dividend will be $3.44 per share. Additionally, the Board of Directors has increased the Company's

    2/10/26 6:33:00 AM ET
    $DGX
    Medical Specialities
    Health Care

    Quest Diagnostics Launches Novel Flow Cytometry MRD Blood Test for Myeloma, Enabling Ultrasensitive Detection of Residual Disease

    New test as sensitive as next-generation sequencing, and provides five-day specimen stability to support nationwide testing SECAUCUS, N.J., Feb. 2, 2026 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced the launch of a novel blood test that uses advanced flow cytometry methods to assess measurable residual disease (MRD) in patients with the blood cancer myeloma (also called multiple myeloma). Called Quest Flow Cytometry MRD for Myeloma, the new test provides comparable sensitivity as next-generation sequencing methods in detecting residual myeloma*, but at a fraction of the cost, supporting better care and outcomes.

    2/2/26 8:52:00 AM ET
    $DGX
    Medical Specialities
    Health Care

    Quest Diagnostics Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits

    8-K - QUEST DIAGNOSTICS INC (0001022079) (Filer)

    2/10/26 6:53:25 AM ET
    $DGX
    Medical Specialities
    Health Care

    Quest Diagnostics Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - QUEST DIAGNOSTICS INC (0001022079) (Filer)

    1/12/26 4:37:53 PM ET
    $DGX
    Medical Specialities
    Health Care

    Quest Diagnostics Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - QUEST DIAGNOSTICS INC (0001022079) (Filer)

    10/21/25 6:50:12 AM ET
    $DGX
    Medical Specialities
    Health Care

    $DGX
    Financials

    Live finance-specific insights

    View All

    Quest Diagnostics Reports Fourth Quarter and Full Year 2025 Financial Results; Provides Guidance for Full Year 2026; Increases Quarterly Dividend 7.5% to $0.86 Per Share

    Fourth quarter revenues of $2.81 billion, up 7.1% from 2024Fourth quarter reported diluted earnings per share ("EPS") of $2.18, up 11.8% from 2024; and adjusted diluted EPS of $2.42, up 8.5% from 2024Full year revenues of $11.04 billion, up 11.8% from 2024Full year reported diluted EPS of $8.75, up 13.8% from 2024; and adjusted diluted EPS of $9.85, up 10.3% from 2024   Full year cash from operations of $1.89 billionFull year 2026 revenues expected to be between $11.70 billion and $11.82 billion Full year 2026 reported diluted EPS expected to be between $9.45 and $9.65; and adjusted diluted EPS expected to be between $10.50 and $10.70SECAUCUS, N.J., Feb. 10, 2026 /PRNewswire/ -- Quest Diagno

    2/10/26 6:47:00 AM ET
    $DGX
    Medical Specialities
    Health Care

    Quest Diagnostics Increases Dividend 7.5% To $0.86 Per Quarter, Marking 15 Consecutive Years of Dividend Increases; Announces $1 Billion Increase in Share Repurchase Authorization

    SECAUCUS, N.J., Feb. 10, 2026 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE:DGX), a leading provider of diagnostic information services, today announced that the Company's Board of Directors has authorized a 7.5% increase in its quarterly cash dividend to $0.86 per share from $0.80 per share. The increase is effective with the dividend payable on April 20, 2026 to shareholders of record of Quest Diagnostics common stock on April 6, 2026. With the increase, the annual cash dividend will be $3.44 per share. Additionally, the Board of Directors has increased the Company's

    2/10/26 6:33:00 AM ET
    $DGX
    Medical Specialities
    Health Care

    Quest Diagnostics to Release Fourth Quarter and Full Year 2025 Financial Results on February 10, 2026

    SECAUCUS, N.J., Jan. 8, 2026 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, today announced that it will report fourth quarter and full year 2025 financial results on Tuesday, February 10, 2026, before the market opens. It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. Eastern Time on that day. The conference call can be accessed by dialing 888-455-0391 within the U.S. and Canada, or 773-756-0467 internationally, using the passcode: "7895081." The earnings release and live webcast

    1/8/26 10:00:00 AM ET
    $DGX
    Medical Specialities
    Health Care

    $DGX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Quest Diagnostics Incorporated (Amendment)

    SC 13G/A - QUEST DIAGNOSTICS INC (0001022079) (Subject)

    2/13/24 5:12:21 PM ET
    $DGX
    Medical Specialities
    Health Care

    SEC Form SC 13G/A filed by Quest Diagnostics Incorporated (Amendment)

    SC 13G/A - QUEST DIAGNOSTICS INC (0001022079) (Subject)

    1/25/24 12:16:40 PM ET
    $DGX
    Medical Specialities
    Health Care

    SEC Form SC 13G/A filed by Quest Diagnostics Incorporated (Amendment)

    SC 13G/A - QUEST DIAGNOSTICS INC (0001022079) (Subject)

    2/7/23 1:25:52 PM ET
    $DGX
    Medical Specialities
    Health Care

    $DGX
    Leadership Updates

    Live Leadership Updates

    View All

    Sonora Quest and Laboratory Sciences of Arizona Announce Jennifer Erickson as CEO-Elect

    Jennifer Erickson succeeds longtime CEO David Dexter following more than 26 years of service PHOENIX, Jan. 15, 2026 /PRNewswire/ -- Sonora Quest Laboratories, together with its parent company Laboratory Sciences of Arizona (LSA), is pleased to announce the appointment of Jennifer Erickson as Chief Executive Officer-Elect. Erickson will take over from David Dexter, who is retiring this March after more than 26 years of leadership. Dexter joined Sonora Quest and LSA as president and CEO in 1999, where under his leadership, the company has grown tremendously, serving as the marke

    1/15/26 9:00:00 AM ET
    $DGX
    Medical Specialities
    Health Care

    Quanterix Appoints Everett Cunningham as President and CEO Effective January 19, 2026

    Planned Leadership Transition Positions Company for Growth Company Expects to Exceed Revenue and Cash Guidance for the Full Year 2025 Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that its Board of Directors (the "Board") has appointed Everett Cunningham as the Company's next President and Chief Executive Officer and a member of the Board, effective January 19, 2026. Mr. Cunningham will succeed Masoud Toloue, who will continue to serve as Chief Executive Officer until Mr. Cunningham assumes the role on January 19, 2026. Following Mr. Cunningham

    1/8/26 4:30:00 PM ET
    $ARVN
    $DGX
    $EXAS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical Specialities
    Biotechnology: Laboratory Analytical Instruments

    Fitbit and Quest Diagnostics Collaborate to Advance Research on the Use of Wearable Devices to Improve Metabolic Health

    Study to evaluate how behavioral and sensor data from wearables and blood tests can be leveraged to help individuals better assess and manage their metabolic health SECAUCUS, N.J., Jan. 17, 2024 /PRNewswire/ -- Fitbit and Quest Diagnostics (NYSE:DGX), the world's leading provider of diagnostic information services, today announced a collaboration to study the potential of wearable devices to improve metabolic health, which influences risk of developing several diseases, including diabetes and heart disease. The Wearables for Metabolic Health (WEAR-ME) pilot study will pair beh

    1/17/24 8:58:00 AM ET
    $DGX
    Medical Specialities
    Health Care